Publications by authors named "J S Burgers"
Background: effectiveness of single disease management programs (DMP) in general practice may be limited for patients with low socioeconomic status (SES), as DMPs insufficiently take into account the specific problems and needs of this population. A Person-Centred Integrated Care (PC-IC) approach focusing on patient's needs could address these problems.
Aim: to explore experiences of patients with (multiple) chronic diseases with regard to the acceptability of a general practice-based PC-IC approach, with a focus on patients with low SES, and to establish which modifications are needed to tailor the approach to this group.
Background: The recommendation to consider prescribing inhalation corticosteroids to a subgroup of vulnerable COVID-19 patients was added to the Dutch medical guideline on November 11, 2021, and was also adopted by other countries during the pandemic.
Aim: To evaluate the adherence of general practitioners to this guideline, and whether real-world data quality is sufficient to study the effect of revised guidelines on prescribing behaviour.
Design & Setting: A retrospective cohort study using Dutch primary care data from the Extramural LUMC Academic Network database, containing patient data of 129 general practices in the Leiden - The Hague area.
Background: Personal continuity is an important dimension of continuity of care in general practice and is associated with many benefits including a higher quality of GP care and lower mortality rate. Over time, changes in society and health care have challenged the provision of personal continuity. Older patients in particular experience more negative consequences from receiving discontinuous care.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates mechanisms of resistance in patients with EGFR mutated non-small cell lung cancer (NSCLC) who progressed on osimertinib treatment, using paired plasma and tumor samples for analysis.
- - Out of 51 patients, the driver mutation was found in 82% of plasma samples and 98% of tumor samples, with a concordance rate of 80%, while resistance mechanisms (RMs) were identified in 80% of patients.
- - The findings suggest that analyzing both plasma and tumor samples provides a more comprehensive understanding of osimertinib resistance, with plasma identifying 61.5% and tumor analysis revealing 75% of RMs, leading to better treatment strategies.
Background: Guideline development on testing is known to be difficult for guideline developers. It requires consideration of various aspects, such as accuracy, purpose of testing, and consequences on management and people-important outcomes. This can be outlined in a test-management pathway.
View Article and Find Full Text PDF